In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Daiichi Sankyo Co., Ltd.

https://www.daiichisankyo.com/index.html

Latest From Daiichi Sankyo Co., Ltd.

Coronavirus Update: Russia Plans First Vaccinations In October

Concern and skepticism about Russia's rapid vaccine roll out. Meanwhile Japan is latest to reach deal with Pfizer/BioNTech.

Coronavirus COVID-19 Vaccines

China Advances Two Coronavirus Vaccines Into Phase III

Chinese state-owned company Sinopharm has started a Phase III coronavirus vaccine study in Abu Dhabi, while another Chinese firm, Sinovac, has commenced its trial with partner Butantan in Brazil. Meanwhile, regulators in Beijing have started an audit process to ensure regulatory compliance.

Coronavirus COVID-19 Vaccines

Oncology Deal-Making The Daiichi Way

Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.

Commercial Deals

AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi

Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.

Commercial Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Ambit Biosciences Corporation
    • Asubio Pharmaceuticals, Inc.
    • Daiichi Sankyo RD Novare Co., Ltd.
    • Kitasato Daiichi Sankyo K.K.
    • Im Co., Ltd., Luitpold Pharmaceuticals, Inc. (American Regent, Inc., PharmaForce, Inc.)
    • Plexxikon Inc.
    • Ranbaxy Laboratories Ltd.
    • Roxro Pharma, Inc.
    • Sankyo Pharma
    • Suntory Pharmaceutical
    • U3 Pharma AG
    • Daiichi Sankyo India Pharma Private Limited
    • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
    • Zenotech Laboratories Ltd.
UsernamePublicRestriction

Register